Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtech VCs Show Steady Hand With Dollars Invested in 2013

This article was originally published in Start Up

Executive Summary

Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.

You may also be interested in...



Venture Investors See Opportunity In Ophthalmology

A review of venture capital investments in ophthalmology-focused biotechs and medtechs over the past five years. Data from Informa's Strategic Transactions.

Toward Spectacle-Free Cataract Surgery

After a lull, or at least a single-minded focus on femtosecond lasers for a time, refractive surgery has gotten exciting again: the drive to spectacle-free outcomes for cataract patients (who have aged-out of their eligibility for other refractive procedures) is calling for solutions that offer precision and accuracy at every stage of treatment. Start-ups coming up with the solutions will be serving some gigantic markets.

ElectroCore Aims To Bring Neurostimulation To The Masses, Beginning With Headache

Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT037946

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel